The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
Open accessAbstract
BACKGROUND: There is no effective treatment strategy for advanced castration-resistant prostate cancer. Although Docetaxel (Taxotere®) represents the most active chemotherapeutic agent it only gives a modest survival advantage with most patients eventually progressing because of inherent or acquired drug resistance. The aims of this study were to further investigate the mechanisms of resistance to Docetaxel. Three Docetaxel resistant sub-lines were generated and confirmed to be resistant to the apoptotic and anti-proliferative effects of increasing concentrations of Docetaxel. RESULTS: The resistant DU-145 R and 22RV1 R had expression of P-glycoprotein and its inhibition with Elacridar partially and totally reversed the resistant phenotype in the two cell lines respectively, which was not seen in the PC-3 resistant sublines. Resistance was also not mediated in the PC-3 cells by cellular senescence or autophagy but multiple changes in pro- and anti-apoptotic genes and proteins were demonstrated. Even though there were lower basal levels of NF-κB activity in the PC-3 D12 cells compared to the Parental PC-3, docetaxel induced higher NF-κB activity and IκB phosphorylation at 3 and 6 hours with only minor changes in the DU-145 cells. Inhibition of NF-κB with the BAY 11-7082 inhibitor reversed the resistance to Docetaxel. CONCLUSION: This study confirms that multiple mechanisms contribute to Docetaxel resistance and the central transcription factor NF-κB plays an immensely important role in determining docetaxel-resistance which may represent an appropriate therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
Klionsky, D. J., Abeliovich, H., Agostinis, P., Agrawal, D. K., Aliev, G., Askew, D. S., Baba, M., Baehrecke, E. H., Bahr, B. A., Ballabio, A., et al. (2008) · Autophagy · doi:10.4161/auto.5338 · Cited by 2,230 · cited 1×
“Total cellular protein was extracted from the different cell lines following Docetaxel treatment (50 nM) and assessed for the expression of LC3 II, a protein associated with autophagosome formation and a marker of autophagy [24].”
MethodMostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Clusterin inhibits apoptosis by interacting with activated Bax
Zhang, H., Kim, J. K., Edwards, C. A., Xu, Z., Taichman, R., & Wang, C.-Y. (2005) · Nature Cell Biology · doi:10.1038/ncb1291 · Cited by 453
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Corcoran, C., Rani, S., O’Brien, K., O’Neill, A., Prencipe, M., Sheikh, R., Webb, G., McDermott, R., Watson, W., Crown, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050999 · Cited by 448
Self-citationMechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
A microfluidic platform for drug screening in a 3D cancer microenvironment
Pandya, H. J., Dhingra, K., Prabhakar, D., Chandrasekar, V., Natarajan, S. K., Vasan, A. S., Kulkarni, A., & Shafiee, H. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.03.054 · Cited by 76
Metadata
- Authors
- O'Neill, A. J., Prencipe, M., Dowling, C., Fan, Y., Mulrane, L., Gallagher, W. M., O'Connor, D., O'Connor, R., Devery, A., Corcoran, C., Rani, S., O'Driscoll, L., Fitzpatrick, J. M., & Watson, R. W. G.
- Venue
- Molecular Cancer
- Published
- 2011
- Volume
- 10
- Issue
- 1
- Pages
- 126
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2106572206
- Cited by
- 229
- References
- 7
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. https://app.cochat.ai/papers/10.1186/1476-4598-10-126
- The paper
- O'Neill, A. J., Prencipe, M., Dowling, C., Fan, Y., Mulrane, L., Gallagher, W. M., O'Connor, D., O'Connor, R., Devery, A., Corcoran, C., Rani, S., O'Driscoll, L., Fitzpatrick, J. M., & Watson, R. W. G. (2011). Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Molecular Cancer. https://doi.org/10.1186/1476-4598-10-126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.